News
Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...
- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...
Eli Lilly is set to pay up to $415 million in an ALS deal with Alchemab Therapeutics. ... Lantheus dropped its experimental radiopharmaceutical for prostate cancer that it partnered with Lilly on.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results